Cold Ethanol Fractionation and Heat Inactivation of Hepatitis a Virus during Manufacture of Albumin from Human Plasma

Biotechnology and Bioprocess Engineering

Volumn 9, Issue 1, 2004, Pages 65-68

  Kim, In Seop ^a   Choi, Yong Woon ^b   Lee, Sung Rae ^b   Sung, Hark Mo ^b  

^a Hannam University   (South Korea)

^b Green Cross Company   (South Korea)

Author keywords

Cold ethanol fractionation; HAV removal and inactivation; Human albumin; Pasteurization

Indexed keywords

EID: 33644784455     PISSN: 12268372     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02949325     Document Type: Article

References (22)

1. Berkman S. A. (1988) Infectious complications of blood transfusion. Blood Rev. 2: 206-210.
2. Schilt, U. (1989) Overview of viruses relevant to blood transfusion. Curr. Stud. Hematol. Blood Transfus. 56: 1-8.
3. Cuthbertson, B., K. G. Reid, and P. R. Foster (1991) Viral contamination of human plasma and procedures for preventing virus transmission by plasma products, pp. 385-435. In: J. R. Harris (ed.). Blood separation and plasma fractionation. Willey-Liss., New York, USA.
4. Cohn, E. J., L. E. Strong, W. L. Hughes Jr, D. J. Mulford, J. N. Ashworth, M. Melin, and H. L. Taylor (1946) Preparation and properties of serum and plasma proteins. IV A system for the separation into fractions of the proteins and lipoprotein components of biological tissues and fluids. J. Am. Chem. Soc. 68: 459-475.
5. Kim, I. S., H. G. Eo, C. E. Chang, and S. Lee (2000) Partitioning and inactivation of viruses by cold ethanol fractionation and pasteurization during manufacture of albumin from human plasma. J. Microbiol. Biotechnol. 10: 858-864.
6. Erstad, B. L. (1996) Viral infectivity of albumin and plasma protein fraction. Pharmacotherapy 16: 996-1001.
7. Roberts, P. (1996) Virus safety of plasma products. Rev. Med. Virol. 6: 25-38.
8. Tabor, E. (1999) The epidemiology of virus transmission by plasma derivatives: Clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39: 1160-1168.
9. Federal Health Office and Paul Ehrlich Institute Federal Office for Sera and Vaccines (1994) Notice on the registration of drugs: Requirements for validation studies to demonstrate the virus safety of drugs derived from human blood or plasma. Bundesanzeiger 84: 4742-4744.
10. International Conference on Harmonisation (1998) Guid-ance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; Availability. Federal Resister 63(185): 51074-51084.
11. Kim, I. S., H. G. Eo, C. W. Park, C. E. Chang, and S. Lee (2001) Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma. Biotechnol. Bioprocess Eng. 6: 25-30.
12. Morgenthaler J. J. and A. Omar (1993) Partitioning and inactivation of viruses during isolation of albumin and immunoglobulins by cold ethanol fractionation. Dev. Biol. Stand. 81: 185-90.
13. Henin Y, V. Marechal, F. Barre-Sinoussi, J. C. Chermann, and J. J. Morgenthaler (1988) Inactivation and partition of human immunodeficiency virus during Kistler and Nitschmann fractionation of human blood plasma. Vox Sang. 54: 78-83.
14. Wells M. A., A. E. Wittek, J. S. Epstein, C. Marcus-Sekura, S. Daniel, D. L. Tankersley, M. S. Preston, and G. V. Quinnan Jr (1986) Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Transfusion 26: 210-213.
15. Yei, S., M. W. Yu, and D. L. Tankersley (1992) Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion 32: 824-828.
16. Andrewes, C. (1989) Andrewes' Viruses of Vertebrates, pp. 120-145. Balliere Tindal, London, UK.
17. Johnson, Z., L. Thornton, A. Tobin, E. Lawlor, J. Power, I. Hillary, and I. Temperley (1995) An outbreak of hepatitis A among Irish haemophiliacs. Int. J. Epidermol. 24: 821-828.
18. Robinson, S. M., H. Schwinn, and A. Smith (1992) Clotting factors and hepatitis A. Lancet 340: 1465.
19. Temperley, I. J., K. P. Cotter, T. J. Walsh, J. Power, and I. B. Hillary (1992) Clotting factors and hepatitis A. Lancet 340: 1466.
20. Kim, I. S., Y. W. Choi, S. R. Lee, Y. Kang, K. M. Lee, D. H. Park, H. S. Woo, and S. Lee (2002) Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine. Biotechnol. Bioprocess Eng. 1: 340-346.
21. Heimburger, N. and H. E. Karges (1989) Strategies to produce virus-safe blood derivatives. Curr. Stud. Hematol. Blood Transfus. 56: 23-33.
22. Nowak, T., M. Niedrig, D. Bernhardt, and J. Hilfenhaus (1993) Inactivation of HIV HBV HCV related viruses and other viruses in human plasma derivatives by pasteurization. Dev. Biol. Stand. 81: 169-176.